Best of ASCO - 2014 Annual Meeting

 

Welcome

Bone Tumors

Sarcoma

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A three-gene signature to predict survival in pediatric osteosarcoma (OS) to follow patients toward liquid biopsy: A collaborative work in OS2006 protocol.

Natacha Entz-Werle

11014

Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517).

Jie Xu

11012

Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS).

Giulia Chiabotto

e22509

Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial.

Lu Xie

11013

Chemotherapy combined with antiangiogenesis drugs in stage IV sarcoma patients: Efficacy data from the largest cohort study from China.

Zhiwu Ren

e22505

Clinical characteristics of nonosteogenic, non-Ewing’s sarcoma of the bone: Experience at the Toronto Sarcoma Program.

Zachary William Neil Veitch

11029

Combination treatment for giant cell tumors of the bone.

Artem A. Barashev

e22504

Comprehensive genomic profiling of patients with favorable prognosis in osteosarcoma.

Weifeng Liu

e22501

Depletion of mutant IDH1 impairs chondrosarcoma growth by downregulating integrins.

Luyuan Li

11031

Effect of miR-506 on pirarubicin sensitivity and on mesenchymal to epithelial transition and DNA damage homologous recombination repair process in leiomyosarcoma.

Jilong Yang

e22503

Evaluation of the TPO-receptor agonist Eltrombopag in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models.

Michael Roth

e22502

Interval-compressed vincristine, doxorubicin, cyclophosphamide (VAC), alternating with ifosfamide and etoposide (IE) for adults with Ewing or Ewing-like sarcoma.

Eric Lu

11025

Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma.

Pascaline Boudou-Rouquette

e22506

Multidisciplinary treatment of 99 adult osteosarcoma (OST) patients (pts) with synchronous and metachronous metastases (mets): A retrospective series of the French Sarcoma Group (FSG).

Elise Lavit

11030

Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).

Nam Bui

11028

Outcomes of extra-skeletal versus skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.

Samer Salah

11027

Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.

Martin G. McCabe

11007

Salvage chemotherapy using irinotecan and temozolamide in pediatric and adult populations with relapsed Ewing sarcoma.

Samer Salah

e22500

Secondary genomic alterations in Ewing sarcoma.

An Uche

11024

The long term surgical outcome of spinal giant cell tumor.

Joonho Yoon

e22510

Toxicity and efficacy of busulfan-melphalan (BuMel) compared to treosulfan-melphalan (TreoMel) high dose chemotherapy (HDCT) consolidation in high-risk Ewing sarcoma (ES): A 12-year monoinstitutional experience.

Massimo Eraldo Abate

e22507

Tumor control with palliative external beam radiation therapy (EBRT) in advanced and unresectable osteosarcoma (OS) progressing after standard treatment.

Francesco Tolomeo

e22508